| IL-17 signaling pathway |
1.82 |
1.87e-1 |
84/94 (89.36%) |
CXCL2;LCN2;S100A7;...
|
| Pyrimidine metabolism |
1.80 |
9.94e-2 |
40/56 (71.43%) |
NME4;DCK;NME1;...
|
| Aminoacyl-tRNA biosynthesis |
1.79 |
7.01e-2 |
15/66 (22.73%) |
NARS2;LARS2;QRSL1;...
|
| TNF signaling pathway |
1.75 |
7.60e-2 |
103/112 (91.96%) |
CXCL2;CASP10;CXCL3;...
|
| Renin secretion |
1.71 |
8.18e-2 |
61/69 (88.41%) |
ADRB2;GNAI1;AGTR1;...
|
| Phosphonate and phosphinate metabolism |
1.71 |
6.82e-2 |
5/6 (83.33%) |
CHPT1;CEPT1
|
| Tyrosine metabolism |
1.68 |
7.85e-2 |
30/36 (83.33%) |
ADH1B;ALDH3A1;TYR;...
|
| Viral protein interaction with cytokine and cytokine re... |
1.67 |
8.47e-2 |
84/100 (84%) |
CXCL2;CXCL3;CXCL1;...
|
| DNA replication |
1.67 |
7.79e-2 |
34/36 (94.44%) |
MCM2;PCNA;MCM5;...
|
| Amoebiasis |
1.66 |
7.60e-2 |
99/102 (97.06%) |
CXCL2;CXCL3;CXCL1;...
|
| Mineral absorption |
1.65 |
7.33e-2 |
48/60 (80%) |
MT1X;MT1HL1;CYBRD1;...
|
| Metabolism of xenobiotics by cytochrome P450 |
1.65 |
7.11e-2 |
49/77 (63.64%) |
ADH1B;ALDH3A1;AKR7A2;...
|
| Cell cycle |
1.63 |
7.73e-2 |
110/124 (88.71%) |
E2F2;CCNB2;MCM2;...
|
| Carbohydrate digestion and absorption |
1.59 |
1.18e-1 |
37/47 (78.72%) |
SLC5A1;PRKCB;ATP1B3;...
|
| Base excision repair |
1.54 |
1.70e-1 |
29/33 (87.88%) |
PCNA;HMGB1;LIG3;...
|
| NOD-like receptor signaling pathway |
1.51 |
1.88e-1 |
145/181 (80.11%) |
CXCL2;CXCL3;CXCL1;...
|
| Drug metabolism |
1.51 |
1.88e-1 |
78/151 (51.66%) |
NME4;ADH1B;ALDH3A1;...
|
| Chemokine signaling pathway |
1.50 |
1.86e-1 |
163/192 (84.9%) |
CXCL2;GNAI1;CXCL3;...
|
| Fat digestion and absorption |
1.49 |
1.91e-1 |
35/43 (81.4%) |
PLA2G2A;PLA2G5;PLA2G10;...
|
| Lipid and atherosclerosis |
1.48 |
1.97e-1 |
190/215 (88.37%) |
CXCL2;CXCL3;CXCL1;...
|
| Purine metabolism |
1.47 |
2.13e-1 |
102/129 (79.07%) |
NME4;GMPR;PRPS2;...
|
| Mucin type O-glycan biosynthesis |
1.47 |
2.05e-1 |
20/36 (55.56%) |
GALNT7;GALNT12;GALNT6;...
|
| Pentose and glucuronate interconversions |
1.47 |
1.97e-1 |
17/34 (50%) |
AKR1B10;DCXR;UGT2B15;...
|
| Fanconi anemia pathway |
1.47 |
1.89e-1 |
36/54 (66.67%) |
ATR;RMI1;PALB2;...
|
| Melanogenesis |
1.45 |
2.07e-1 |
74/101 (73.27%) |
GNAI1;PRKACB;CTNNB1;...
|
| Salivary secretion |
1.41 |
2.64e-1 |
76/93 (81.72%) |
ADRB2;PRKACB;DMBT1;...
|
| Retinol metabolism |
1.41 |
2.54e-1 |
41/68 (60.29%) |
ALDH1A1;ADH1B;ALDH1A2;...
|
| Gap junction |
1.41 |
2.47e-1 |
72/88 (81.82%) |
GNAI1;PRKACB;SRC;...
|
| Neomycin, kanamycin and gentamicin biosynthesis |
1.40 |
2.60e-1 |
5/5 (100%) |
HK2;HKDC1
|
| Intestinal immune network for IgA production |
1.39 |
2.61e-1 |
38/48 (79.17%) |
HLA-DQA1;PIGR;HLA-DRA;...
|
| Measles |
-1.25 |
5.10e-1 |
133/139 (95.68%) |
JAK1;AKT2;IRF9;...
|
| Mannose type O-glycan biosynthesis |
-1.25 |
5.14e-1 |
14/23 (60.87%) |
FKRP;B4GALT3;CHST10;...
|
| Protein processing in endoplasmic reticulum |
-1.30 |
4.52e-1 |
127/171 (74.27%) |
EIF2AK1;HSPA6;DERL1;...
|
| Sulfur relay system |
-1.32 |
4.25e-1 |
5/8 (62.5%) |
TST;MOCS2
|
| Cysteine and methionine metabolism |
-1.32 |
4.23e-1 |
43/50 (86%) |
GOT1;TST;BHMT;...
|
| Circadian rhythm |
-1.33 |
4.18e-1 |
26/31 (83.87%) |
CLOCK;RBX1;BHLHE40;...
|
| Toll-like receptor signaling pathway |
-1.33 |
4.27e-1 |
94/104 (90.38%) |
TBK1;PIK3CA;TLR3;...
|
| Glycosphingolipid biosynthesis |
-1.35 |
4.00e-1 |
37/57 (64.91%) |
B3GNT2;ST6GALNAC4;ST3GAL6;...
|
| Synaptic vesicle cycle |
-1.35 |
4.07e-1 |
63/78 (80.77%) |
ATP6V0D1;DNM1;UNC13B;...
|
| Viral myocarditis |
-1.40 |
3.06e-1 |
53/60 (88.33%) |
CAV1;CD86;MYH7;...
|
| Cell adhesion molecules |
-1.40 |
3.17e-1 |
118/148 (79.73%) |
CD22;NECTIN3;HLA-G;...
|
| Nicotinate and nicotinamide metabolism |
-1.42 |
2.77e-1 |
25/35 (71.43%) |
SIRT7;NNT;SIRT2;...
|
| Thyroid cancer |
-1.43 |
2.88e-1 |
36/37 (97.3%) |
CDH1;PPARG;MAP2K1;...
|
| Phagosome |
-1.44 |
2.66e-1 |
118/152 (77.63%) |
ATP6V1A;ATP6V1C1;FCGR2C;...
|
| MAPK signaling pathway |
-1.45 |
2.73e-1 |
272/294 (92.52%) |
KIT;MAPK9;EGFR;...
|
| Ferroptosis |
-1.48 |
2.20e-1 |
36/41 (87.8%) |
SLC39A14;PRNP;ATG5;...
|
| Glycine, serine and threonine metabolism |
-1.50 |
2.03e-1 |
31/40 (77.5%) |
PSPH;GRHPR;ALDH7A1;...
|
| Osteoclast differentiation |
-1.51 |
2.12e-1 |
117/127 (92.13%) |
PIK3CA;PIK3CB;MAPK11;...
|
| Leishmaniasis |
-1.51 |
2.27e-1 |
67/77 (87.01%) |
MAPK13;ITGB2;TGFB2;...
|
| Citrate cycle (TCA cycle) |
-1.54 |
1.84e-1 |
30/30 (100%) |
SDHB;SUCLA2;SUCLG2;...
|
| RNA degradation |
-1.55 |
1.81e-1 |
53/79 (67.09%) |
C1D;CNOT4;DCP2;...
|
| Proteoglycans in cancer |
-1.55 |
1.93e-1 |
172/205 (83.9%) |
HCLS1;NANOG;SOS1;...
|
| Propanoate metabolism |
-1.56 |
2.13e-1 |
30/34 (88.24%) |
LDHA;PCCA;PCCB;...
|
| Valine, leucine and isoleucine degradation |
-1.57 |
2.28e-1 |
42/48 (87.5%) |
ABAT;ACAA2;HMGCS1;...
|
| Fluid shear stress and atherosclerosis |
-1.59 |
2.09e-1 |
123/139 (88.49%) |
CAV2;KDR;PIK3CA;...
|
| Collecting duct acid secretion |
-1.59 |
2.45e-1 |
22/27 (81.48%) |
ATP6V1A;ATP6V1C1;ATP6V1E1;...
|
| Cardiac muscle contraction |
-1.68 |
1.09e-1 |
64/87 (73.56%) |
TNNT2;MYH7;CASQ2;...
|
| Hypertrophic cardiomyopathy |
-1.75 |
8.29e-2 |
81/90 (90%) |
CACNG4;PRKAB1;IGF1;...
|
| Malaria |
-1.79 |
7.29e-2 |
44/50 (88%) |
COMP;HGF;THBS1;...
|
| Dilated cardiomyopathy |
-1.81 |
1.37e-1 |
86/96 (89.58%) |
ADCY9;CACNG4;IGF1;...
|
